Regenicin, Inc. is a biotechnology company based in Little Falls, NJ, specializing in regenerative cell therapies for damaged tissues and organs. Their flagship product, NovaDerm, utilizes cultured cell technology to generate living, tissue-engineered skin from the patient's own skin cells, offering a groundbreaking treatment for severe burns. With the ability to grow a graft area one hundred times the size of a harvested skin section in just thirty days, Regenicin is at the forefront of developing innovative solutions for burn victims.
Through successful collaborations and regulatory milestones, Regenicin has demonstrated its commitment to advancing the field of regenerative medicine. Their recent supplier agreement with Pure Med Farma LLC for closed herd collagen and completion of a pre-IND meeting with the FDA further solidify their position as a leader in the industry. With a focus on research, manufacturing, and the development of other potential products, Regenicin continues to pave the way for the future of regenerative cell therapies.
Generated from the website